The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.

Clin Breast Cancer 2016 10 17;16(5):372-378. Epub 2016 Mar 17.

Breast Care Centre, Hong Kong Sanatorium and Hospital, Hong Kong Breast Cancer Foundation, Hong Kong. Electronic address:

Background: The Oncotype DX Breast Cancer Assay is validated to assess risk of distant recurrence and likelihood of chemotherapy (CT) benefit in estrogen receptor-positive ESBC in various populations. In Hong Kong, > 80% of breast cancers are early stage breast cancer (ESBC) and > 60% of these women receive CT. This prospective study measured changes in CT type and recommendations, as well as physician impression of assay impact in a homogenous Chinese population.

Methods: Consecutive patients with estrogen receptor-positive, T1-3 N0-1mi M0 ESBC were offered enrollment. After surgery, physicians discussed treatment options with patients, then ordered the assay, then reassessed treatment recommendation considering assay results. Changes in treatment recommendation, CT utilization, physician confidence, and physician rating of influence on their treatment recommendations were measured.

Results: A total of 146 evaluable patients received pre- and post-testing treatment recommendations. CT recommendations (including changes in intensity of CT) were changed for 34 of 146 patients (23.3%; 95% confidence interval, 16.7%-31.0%); change in intensity occurred in 7 of 146 (4.8%). There were 27 changes in treatment recommendations of adding or removing CT altogether (18.5% change; 95% confidence interval, 12.6%-25.8%). CT recommendations decreased from 52.1% to 37.7%, a net absolute reduction of 14.4% (P < .001; 27.6% net relative reduction). Pre-assay, 96% of physicians agreed/strongly agreed that they were confident in their treatment recommendation; post-assay, 90% of physicians agreed/strongly agreed with the same statement. Thirty percent of physicians agreed/strongly agreed that the test had influenced their recommendation, similar to the proportion of changed recommendations.

Conclusions: The Oncotype DX Assay appears to influence physician ESBC adjuvant treatment recommendations in Hong Kong.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2016.03.002DOI Listing
October 2016
26 Reads

Publication Analysis

Top Keywords

treatment recommendations
16
hong kong
12
agreed/strongly agreed
12
physicians agreed/strongly
12
treatment recommendation
12
estrogen receptor-positive
12
breast cancer
12
treatment
9
confidence interval
8
oncotype breast
8
changes treatment
8
cancer assay
8
95% confidence
8
recommendations
7
assay
6
breast
5
intensity occurred
4
post-testing treatment
4
patients received
4
evaluable patients
4

Similar Publications